136 related articles for article (PubMed ID: 2938984)
1. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
Gudmundsson JA; Nillius SJ; Bergquist C
Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
Gudmundsson JA; Nillius SJ; Bergquist C
Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
[TBL] [Abstract][Full Text] [Related]
3. Ovulation inhibition with nafarelin acetate nasal administration for six months.
Brenner PF; Shoupe D; Mishell DR
Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.
Nillius SJ
J Steroid Biochem; 1985 Nov; 23(5B):849-54. PubMed ID: 2934581
[TBL] [Abstract][Full Text] [Related]
5. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
6. Peptide contraception by inhibition of ovulation with intranasal GnRH superagonist: clinical and metabolic aspects.
Gudmundsson JA; Bergquist C; Nillius SJ
Prog Clin Biol Res; 1986; 225():337-51. PubMed ID: 2947248
[TBL] [Abstract][Full Text] [Related]
7. Endometrial morphology after 6 months of continuous treatment with a new gonadotropin-releasing hormone superagonist for contraception.
Gudmundsson JA; Lundkvist O; Bergquist C; Lindgren A; Nillius SJ
Fertil Steril; 1987 Jul; 48(1):52-6. PubMed ID: 2954864
[TBL] [Abstract][Full Text] [Related]
8. A new superagonist of GnRH for inhibition of ovulation in women.
Nillius SJ; Gudmundsson J; Bergquist C
Ups J Med Sci; 1984; 89(2):147-50. PubMed ID: 6235657
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).
Monroe SE; Blumenfeld Z; Andreyko JL; Schriock E; Henzl MR; Jaffe RB
J Clin Endocrinol Metab; 1986 Dec; 63(6):1334-41. PubMed ID: 2946710
[TBL] [Abstract][Full Text] [Related]
10. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
Bergquist C; Nillius SJ; Wide L; Lindgren A
Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
[TBL] [Abstract][Full Text] [Related]
11. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: significance of time in cycle.
Monroe SE; Henzl MR; Martin MC; Schriock E; Lewis V; Nerenberg C; Jaffe RB
Fertil Steril; 1985 Mar; 43(3):361-8. PubMed ID: 3156770
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
Bouchard P; Wolf JP; Hajri S
Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
[TBL] [Abstract][Full Text] [Related]
13. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
14. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
15. Contraceptive properties of luteinising hormone releasing hormone.
Lambe RF; Werner-Zodrow I; Darragh A; Mall-Häfeli M
Lancet; 1979 Oct; 2(8146):801. PubMed ID: 90901
[TBL] [Abstract][Full Text] [Related]
16. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
17. Dose-related changes in LH bioactivity with intranasal GnRH agonist administration.
Chiang RS; Barnes RB; Shoupe D; Lobo RA
Contraception; 1985 Oct; 32(4):347-57. PubMed ID: 2934222
[TBL] [Abstract][Full Text] [Related]
18. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin).
Schriock ED; Monroe SE; Martin MC; Henzl MR; Jaffe RB
Fertil Steril; 1985 Jun; 43(6):844-50. PubMed ID: 3158549
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone releasing hormone analogues for contraception.
Nillius SJ
Clin Obstet Gynaecol; 1984 Dec; 11(3):551-72. PubMed ID: 6391776
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
Nillius SJ; Bergquist C; Wide L
Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
